Eli Lilly and Company (NYSE:LLY) Shares Sold by West Oak Capital LLC

West Oak Capital LLC lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,444 shares of the company’s stock after selling 285 shares during the period. Eli Lilly and Company accounts for approximately 2.2% of West Oak Capital LLC’s portfolio, making the stock its 6th largest position. West Oak Capital LLC’s holdings in Eli Lilly and Company were worth $4,786,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. Fairfield Bush & CO. acquired a new stake in shares of Eli Lilly and Company during the first quarter worth about $107,000. Roundview Capital LLC boosted its stake in shares of Eli Lilly and Company by 2.6% during the first quarter. Roundview Capital LLC now owns 2,056 shares of the company’s stock worth $589,000 after buying an additional 53 shares during the period. Merit Financial Group LLC acquired a new stake in shares of Eli Lilly and Company during the first quarter worth about $210,000. NewEdge Advisors LLC boosted its stake in shares of Eli Lilly and Company by 9.9% during the first quarter. NewEdge Advisors LLC now owns 53,052 shares of the company’s stock worth $15,193,000 after buying an additional 4,774 shares during the period. Finally, Barometer Capital Management Inc. acquired a new stake in Eli Lilly and Company in the first quarter valued at about $561,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on LLY shares. Truist Financial reiterated a “buy” rating and set a $850.00 price target on shares of Eli Lilly and Company in a research report on Friday, March 22nd. DZ Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a research report on Wednesday, February 21st. Wells Fargo & Company lifted their price target on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Bank of America lifted their price target on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Finally, BMO Capital Markets raised their price objective on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $689.52.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 1,180 shares of the business’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $645.60, for a total transaction of $761,808.00. Following the completion of the sale, the insider now owns 99,542,630 shares of the company’s stock, valued at approximately $64,264,721,928. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold a total of 195,055 shares of company stock valued at $125,254,657 in the last quarter. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Up 1.5 %

LLY stock traded up $11.92 during trading on Thursday, reaching $790.10. The stock had a trading volume of 1,034,542 shares, compared to its average volume of 3,199,716. Eli Lilly and Company has a 1-year low of $334.58 and a 1-year high of $800.78. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The company has a market capitalization of $750.72 billion, a P/E ratio of 135.99, a PEG ratio of 1.70 and a beta of 0.34. The firm has a fifty day moving average price of $727.96 and a 200 day moving average price of $636.01.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The firm had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm’s revenue was up 28.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.09 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 12.42 earnings per share for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.